Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron

The Omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was initially identified in November 2021 South Africa and Botswana, as well a sample from traveller Hong Kong1,2. Since then, has been detected globally. This appears to be at least infectious Delta (B.1.617.2), already caused superspreader events3, outcompeted within weeks several countries metropolitan areas. hosts an unprecedented number mutations its spike gene early reports have provided evidence for extensive immune escape reduced vaccine effectiveness2,4,5,6. Here we investigated the virus-neutralizing protein-binding activity sera convalescent, double mRNA-vaccinated, mRNA-boosted, convalescent double-vaccinated boosted individuals against wild-type, Beta (B.1.351) SARS-CoV-2 isolates proteins. Neutralizing participants undetectable or very low compared with wild-type virus, whereas neutralizing who had exposed three four times through infection vaccination maintained, although significantly levels. Binding receptor-binding N-terminal domains protein binding wild type unvaccinated individuals, but mostly retained vaccinated individuals.